<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/11672B3D-DE8D-4059-968E-1293C0B50844"><gtr:id>11672B3D-DE8D-4059-968E-1293C0B50844</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Christopher</gtr:otherNames><gtr:surname>Taussig</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501940"><gtr:id>E4746929-B047-498B-B048-02B90490F57B</gtr:id><gtr:title>Elucidation of the mechanism of bone marrow failure in acute myeloid leukaemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0501940</gtr:grantReference><gtr:abstractText>Leukaemia is a type of bone marrow cancer. Leukaemia prevents the bone marrow from doing its job, that is to make healthy blood cells. These blood cells include red cells that carry the oxygen round the body, white cells that fight infection and platelets that help the blood clot. Patients with leukaemia suffer from a deficiency of these cells and consequently become breathless or tired (low red cell numbers), are vulnerable to severe infection (low white blood cell numbers) and bleed spontaneously (low platelet numbers). Although we can replace the red cells by blood transfusion it is not possible to replace platelets and white blood cells effectively. Therefore patients with leukaemia frequently develop infections and bleeding, and many die from these complications.
The cells in the normal bone marrow that make all the blood cells are called stem cells. These stem cells are present in patients with leukaemia but appear to be prevented from working by the leukaemia. The aim of this project is to find out how the leukaemia stops the stem cells from working. By understanding how leukaemia inhibits stem cells we hope to be able to develop treatments to overcome this problem.</gtr:abstractText><gtr:technicalSummary>Acute myeloid leukaemia (AML) induces bone marrow failure (BMF), leading to significant morbidity and mortality. Haematopoietic stem cells (HSCs) are present at diagnosis in patients with AML and patients show regeneration of normal haematopoietic tissue following successful clearance of leukaemic blasts by chemotherapy. This suggests that the HSCs are being prevented from synthesising mature blood cells by the leukaemia. The aim of this study is to elucidate the mechanism by which AML inhibits the HSCs. Under normal circumstances HSC numbers and function are regulated by bone marrow stromal cells such as osteoblasts. These supportive cells make up the HSC ?niche?. We will explore whether AML cells directly inhibit HSCs or whether AML disrupts the supportive HSC ?niche?. There is considerable evidence that T cells contribute to BMF in related myeloid disorders (eg.aplastic anaemia, myelodysplastic syndrome). We will therefore also investigate the role of the host immune system in the BMF induced by leukaemia.
 We will study the direct effects of blood cells from patients with leukaemia on haematopoiesis by culturing them with normal haematopoieitic cells. After the culture, we will assess the number of progenitors and HSCs within the normal haematopoietic cells. By dissecting out specific cell populations (e.g. leukaemic blasts, T cells) from the patient samples using immunomagnetic depletion we will determine which cells are responsible for inhibiting the HSCs and progenitors.
 We will spectratype T cells from AML patients to look for evidence of clonal expansion. The reactivity and effect of these T cells against autologous HSCs will be assessed using ELISPOT and repopulation assays, respectively. 
 The effect of leukaemia on the stem cell ?niche? will be investigated by determining osteoblast numbers in AML-infiltrated marrow using immunohistochemistry. AML may not disrupt the ?niche? but may compete for it. Therefore dependence of the leukaemithese osteoblasts will be assessed by determining whether parathyroid hormone (that increases osteoblast numbers) increases the leukaemic burden in a xenotransplant model. We will also see whether AML cells can displace normal HSCs from the osteoblasts using this same model.
 Finally, we will elucidate the molecular pathways responsible for inhibiting the HSCs by contrasting the gene expression profile of HSCs isolated from patients and controls. The phenotype and repopulating capacity of the HSCs will also be compared.
 By understanding the mechanism by which leukaemia inhibits haematopoiesis it may be possible to intervene and reverse the BMF.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-09-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>970479</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>Academic</gtr:description><gtr:id>1D19155C-7119-475B-8FD5-3A9F88E1A8FC</gtr:id><gtr:impact>Two publications have resulted both in Blood</gtr:impact><gtr:outcomeId>A9F9F9461AE-1</gtr:outcomeId><gtr:partnerContribution>Provision of immunodeficient mice</gtr:partnerContribution><gtr:piContribution>I have collaboration with a researcher at CRUK London Research Institute. I have performed all the in vivo experiments in her laboratory. I generated the idea for the research and performed the research.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>195000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Clinical Research Fellowship</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>D8368DD7-7FB1-4BA2-8AC2-E76CFA23B3B8</gtr:id><gtr:outcomeId>MKsyY8D7kqv0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The work on the effect of antibodies on engraftment of AML in NOD/SCID mice showed that the anti-CD38 antibody has a profound inhibitory effect. This is selective for AML as compared to normal haematopoietic stem cells. The data generated provide a strong indication that the antibody may be utilisable in the clinic for treatment of AML. I have contacted Genmab who have a humanised antibody that is in phase I studies in myeloma patients. Following the trial in myeloma we are now planning to extend the use of anti-CD38 antibody in AML.</gtr:description><gtr:id>3F6CE06A-05D8-4513-8F47-6F2FE472AC4F</gtr:id><gtr:impact>Possible improved outcome in AML</gtr:impact><gtr:outcomeId>343BF85009C</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>anti-CD38 antibody</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7816204E-1103-4931-A830-ACF3D1DAF25D</gtr:id><gtr:title>Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79ecc8a1617fdf7c6d1e49f1a74a1838"><gtr:id>79ecc8a1617fdf7c6d1e49f1a74a1838</gtr:id><gtr:otherNames>Le Dieu R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>4D373156BD2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E82FB793-4B69-4FBF-90BE-C5939FCB0B6D</gtr:id><gtr:title>Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20400ce5bc04839e265d5c4166733e7a"><gtr:id>20400ce5bc04839e265d5c4166733e7a</gtr:id><gtr:otherNames>Joshi NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_14568_28_22225419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25403615-8448-42AF-97A6-481E8CC97CC6</gtr:id><gtr:title>T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1239c27ee29f17606da3ff1b02bd4d0a"><gtr:id>1239c27ee29f17606da3ff1b02bd4d0a</gtr:id><gtr:otherNames>Auer RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_14568_28_22449197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B4423B6-ACE7-467C-8391-BBBD78280B66</gtr:id><gtr:title>Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41f860af1ef552bca736de348a1801e5"><gtr:id>41f860af1ef552bca736de348a1801e5</gtr:id><gtr:otherNames>Vargaftig J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_14568_28_21926966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86BC0334-5068-4655-AAFC-A44F7B9FD27A</gtr:id><gtr:title>Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79ecc8a1617fdf7c6d1e49f1a74a1838"><gtr:id>79ecc8a1617fdf7c6d1e49f1a74a1838</gtr:id><gtr:otherNames>Le Dieu R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>D989B0681A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>527FDAF4-DF7A-40C4-A5B7-6A3745016F59</gtr:id><gtr:title>Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cba988021bfb018901c87cbc216c4d45"><gtr:id>cba988021bfb018901c87cbc216c4d45</gtr:id><gtr:otherNames>Taussig DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>76560F3EDC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2619F574-3052-4B02-9465-1F3077918882</gtr:id><gtr:title>Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29e945fb10eb2c169288e6764e7010ca"><gtr:id>29e945fb10eb2c169288e6764e7010ca</gtr:id><gtr:otherNames>Miraki-Moud F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14568_28_23901108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1944C005-82F4-4AD3-9711-1E0D19395BFF</gtr:id><gtr:title>Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cba988021bfb018901c87cbc216c4d45"><gtr:id>cba988021bfb018901c87cbc216c4d45</gtr:id><gtr:otherNames>Taussig DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>1E59BFB9772</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501940</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>